Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
TRVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.36 - $7.48
Previous CloseN/A
Volume226.18K
Average Volume (3M)1.91M
Market Cap
$754.78M
Enterprise Value$121.15M
Total Cash (Recent Filing)$103.26M
Total Debt (Recent Filing)$957.00K
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Aug 07, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding119,144,770
10 Day Avg. Volume2,974,066
30 Day Avg. Volume1,913,862
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.40
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue344.19
Enterprise Value/Gross Profit-3.19K
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$21.25Price Target Upside250.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Trevi Therapeutics News
PremiumCompany Announcements
Trevi Therapeutics Stockholders Approve Key Amendments
Bulls Say, Bears Say
Bulls Say
Drug EfficacyHaduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups, indicating strong efficacy.
Financial PerformanceTRVI completed a $115M public offering, extending cash runway into 2029 and supporting execution of a Ph 3 study for Haduvio in IPF cough.
Bears Say
Funding ConcernsThere is a perceived overhang regarding the need for significant funding to finance Phase 3 trials, despite having a runway into the fourth quarter of 2026.
Market PerceptionThe Street is misunderstanding Haduvio risk-benefit profile.
Ownership Overview
11.82% Insiders
4.77% Mutual Funds
54.00% Other Institutional Investors
22.49% Public Companies and Individual Investors
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $2.36 and its highest was $7.48 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $754.78M.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Aug 07, 2025 which is in 48 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on May 08, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.033.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.11.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 119,144,770 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
Trevi Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.25 (250.08% Upside)
$21.25 (250.08% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.65%
12-Months-Change
Fundamentals
Return on Equity
-55.12%
Trailing 12-Months
Asset Growth
36.21%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
TRVI Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical achievements with successful trial outcomes and a strong financial position. However, these positives were offset by a continued net loss and increased expenses. The positive aspects slightly outweigh the negatives, suggesting a cautiously optimistic outlook.Read More>TRVI Stock 12 Month Forecast
Average Price Target
$21.25
▲(250.08%Upside)
Technical Analysis
Prothena
―
Rocket Pharmaceuticals
―
AnaptysBio
―
Dianthus Therapeutics
―
Pharming Group
―